Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL
Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data
https://www.fiercebiotech.com/biotech/moderna-dinged-lukewarm-flu-data-waits-efficacy-readout-charting-regulatory-course
After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique
https://www.nytimes.com/2023/02/23/science/moderna-covid-vaccine-patent-nih.html
Moderna reported quarterly earnings of $3.61 per share
The figure fell short of the $4.68 a share Wall Street expected
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61
Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12
Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets
https://investors.modernatx.com/news/news-details/2023/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-Business-Updates/default.aspx
huge news cancer...
today: MODERNA TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 23, 2023
let's see what happens!
OK man $MRNA winner!
fake news!
Health Canada Authorizes MRNA Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
https://investors.modernatx.com/news/news-details/2023/Health-Canada-Authorizes-Modernas-Omicron-Targeting-Bivalent-COVID-19-Vaccine-in-Children--Adolescents-6-17-Years/default.aspx
Moderna said it has already updated mRNA-1010 in a way it believes will improve immune responses against Influenza B and will test those changes.
The first per protocol interim analysis of efficacy is now expected to be reviewed by an independent Data and Safety Monitoring Board (DSMB) before the end of the first quarter. Based on these results the DSMB will notify the Company whether the primary efficacy endpoint has been met or whether the study should continue accruing further cases towards the final analysis.
That’s the beauty of live
relax$
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards :let's see what happens
The Zacks Consensus Estimate and our model estimate for fourth-quarter product sales stand at $5.02 billion and $4.82 billion, respectively.
https://finance.yahoo.com/news/moderna-mrna-report-q4-earnings-151003349.html
relax: "Today's results represent an important step forward in the development of mRNA-based influenza vaccines to address the substantial burden of disease caused by influenza. We are encouraged by the safety and tolerability profile, and by the strong immunogenicity results against Influenza A viruses which cause the overwhelming majority of flu-related disease in older adults. We now look forward to the efficacy results from the ongoing pivotal Phase 3 efficacy study being conducted in parallel," said Stephen Hoge, M.D., Moderna's President. "While we did not achieve non-inferiority for the Influenza B strains which are more frequent in younger populations, we have already updated the vaccine that we believe could improve immune responses against Influenza B and will seek to quickly confirm those improvements in an upcoming clinical study thanks to the agility of our mRNA platform."
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx
Moderna will keep its COVID vaccine on the market at no cost to consumers, even after the federal government stops paying for it, the company announced Wednesday.
"Everyone in the United States will have access to Moderna's COVID-19 vaccine regardless of their ability to pay," the company said in a statement.
Last month, the vaccine maker was slammed for reportedly considering a dramatic price increase for the shot, which it had developed with the help of the federal government.
https://abcnews.go.com/Health/moderna-covid-vaccine-remain-free-consumers-uninsured/story?id=97226324
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
https://finance.yahoo.com/news/u-backs-moderna-says-government-170221948.html
Fossil evidence reveals that cancer in humans goes back 1.7 million years
https://theconversation.com/fossil-evidence-reveals-that-cancer-in-humans-goes-back-1-7-million-years-63430
Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask
https://finance.yahoo.com/news/cancer-vaccines-already-reality-doctor-110000530.html
$MRNA
Let it go and it won't ever happen.
The study enrolled melanoma patients who had undergone surgery to remove any signs of their cancer. Unlike vaccines the public is used to taking — mass-produced shots that aim to prevent people from catching a contagious disease like the flu or polio, Moderna’s cancer vaccine instead is intended to keep the disease from returning. It does that by training immune cells to recognize as dangerous proteins found on a patient’s own tumor cells.
Stephane Bancel told CNBC recently that the company is moving aggressively into Phase 3 studies with the belief that “anywhere Keytruda works, this should work.”
Keytruda, meanwhile, is approved to treat a long list of cancers beyond melanoma—so many, in fact, that it’s expected to bring in more than $24 billion in sales in 2023. Bancel suggested that the vaccine might even make possible responses in tumors where Keytruda has failed, either on its own or by acting synergistically with Merck’s drug.
Another immense challenge is the very high likely cost of a personalized therapy on top of Keytruda, which on its own carries a list price of around $185,000 per year. The only upside to that hefty price tag is that the companies will be motivated to answer these questions as quickly as possible. Indeed, Bancel has said that Moderna plans to aggressively invest in cancer.
So let's see what happens with this Beast.
Yes, I think so......
personalized mRNA vaccine reduced risk of recurrence or death in melanoma.
In the cancer vaccine, the mRNA encodes for tumor-specific mutations called neoantigens. The body creates copies of these neoantigens, learns to recognize them, and creates more immune cells that can target them, therefore fighting the cancer.
The shot, when combined with Merck’s checkpoint inhibitor Keytruda, reduced the risk of cancer recurrence or death by 44% compared to Keytruda alone over a period of 1 year. It was tested in people with stage 3/4 melanoma who had their tumors removed but had a higher chance of the cancer returning due to features of their melanoma
Moderna and Merck plan to initiate a Phase 3 study in people with melanoma in 2023.
So let's see what happens with this Beast.
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
https://www.businesswire.com/news/home/20230203005108/en/Personalis-and-Moderna-Sign-New-Agreement-to-Leverage-NeXT-Platform%E2%84%A2-in-Personalized-mRNA-Cancer-Vaccine-Clinical-Trials
LOL.....LOL.....
Is Moderna (MRNA) a High Growth Stock: https://finance.yahoo.com/news/moderna-mrna-high-growth-stock-050325327.html
Moderna has roughly $18 billion of cash on its balance sheet as of December 31, 2022.....huge
mRNA-1345 was previously granted Fast Track designation by the FDA in August 2021. Moderna intends to submit a license application for regulatory approval in the first half of 2023.
A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.
https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
$MRNA winner
MODERNA GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR MRNA-1345, AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE CANDIDATE
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
https://investors.modernatx.com/news/news-details/2023/Moderna-Granted-FDA-Breakthrough-Therapy-Designation-for-mRNA-1345-An-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Candidate/default.aspx
The biotech has a total of 48 programs in development across many therapeutic areas. If even a handful are successful, we could be looking at major earnings down the road. All of this means Moderna's growth story may just be getting started. And now is the time to jump on board.
Moderna expects a post-pandemic vaccine market in the range of $12 billion to $24 billion. The company also has spoken of charging up to $130 for its vaccine; that's up from about $25 today.
The trial results were impressive:
On Jan. 17, Moderna announced that its RSV vaccine was highly effective in phase 3 trials in preventing the risk of lower respiratory disease (where there were at least two symptoms) in people aged 60 and over. The rate of efficacy was 83.7%. That's slightly higher than the 82.6% efficacy that GSK reported from its vaccine in October, and well above the 66.7% that rival Pfizer achieved when it announced its trial results a few months earlier in August.
The RSV market is an attractive one. Morgan Stanley analysts project that it could be worth between $7 billion and $10 billion....
Moderna is hiring 2,000 employees this year. Here's where they'll be.
https://www.bizjournals.com/boston/news/2023/01/23/moderna-2023-hiring-plans-2000-employees-massachu.html?utm_source=sy&utm_medium=nsyp&utm_campaign=yh
$MRNA winner
Our CEO Stéphane Bancel :
Our CEO Stéphane Bancel joins colleagues at @FlagshipPioneer to discuss digital first, growing R&D budget, #cancer breakthroughs, Moderna's progress in addressing respiratory illnesses, and a growing leadership in #genomics. #FlagshipJPM #JPM23 pic.twitter.com/fjRhROdcdp
— Moderna (@moderna_tx) January 20, 2023
Inhaled pulmonary therapeutics
Cystic fibrosis (CF)
Moderna's collaborator, Vertex Pharmaceuticals, announced that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for VX-522, an mRNA targeted at treating the underlying cause of cystic fibrosis for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator
VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle. Once delivered to the target lung cells, the mRNA is designed to produce functional copies of the CFTR protein
relax$$$$$$
Moderna increases investments in R&D, manufacturing infrastructure, and company buildout, and pursues external investment opportunities (licenses and/or M&A). R&D investments in 2023 are estimated at $4.5 billion, up from approximately $3.3 billion (unaudited) for 2022.....
$MRNA big company!
Moderna Aims to Supply COVID Vaccine to China:
https://learningenglish.voanews.com/a/moderna-aims-to-supply-covid-vaccine-to-china/6923740.html
countdown$$$$$$$$$$
RNA : this is the future .......moderna Founder and pioneer....
$MRNA money machine $$$$$$$$$$$$
DAVOS, Switzerland, Jan 18 (Reuters) - Moderna chief executive Stephane Bancel said on Wednesday the U.S. company was in active discussions to supply COVID-19 vaccines to China.
Speaking to Reuters on the sidelines of the World Economic Forum annual meeting in Davos, he said the talks with Beijing also covered the topic of factories, and other products including cancer treatments
https://finance.yahoo.com/news/1-davos-2023-moderna-ceo-114557785.html
Moderna intends to submit for regulatory approval in the first half of 2023. The trial is ongoing, and additional efficacy analyses are planned as cases accrue, including for severe RSV..........
HUGE: mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults...
MULTIBAGGER$
$MRNA
Richard Torbett, Chief Executive, ABPI, said:
“I’m delighted to welcome Moderna into membership as a world-leading pharmaceutical company that can help bring the UK closer to realising its ambitions to be a leading global centre for life sciences.
“With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.”
$MRNA big company!
Moderna joins the Association of the British Pharmaceutical Industry:
https://www.abpi.org.uk/media/news/2023/january/moderna-joins-the-association-of-the-british-pharmaceutical-industry/